Tirzepatide (GLP-1/GIP): 10mg

Regulatory Notice (August 2026): On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list — finding no clinical need for compounding. The public comment period, initially set to close June 29, 2026, was extended and formally closed on July 30, 2026 (3,901 public comments received). The FDA is now reviewing submitted comments before issuing a final rule (expected within 6–12 months). If finalized, 503B outsourcing facilities will be permanently barred from compounding these agents from bulk API, even if future drug shortages arise. Patient-specific 503A compounding remains a separate pathway. Sources: FDA.gov (April 30, 2026); Federal Register 2026-08552; Medical Daily (July 30, 2026); Science-Based Medicine. FDA Label Expansion — Cardiovascular Risk Reduction (August 28, 2026): The FDA approved a new indication for tirzepatide (Mounjaro; Eli Lilly) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. This approval was based on the SURPASS-CVOT cardiovascular outcomes trial. This is a label expansion for an already-approved prescription drug (Mounjaro). Compounded tirzepatide remains outside this approval — the expanded label applies solely to the brand-name pharmaceutical product. Source: Eli Lilly investor press release (investor.lilly.com, August 28, 2026); Cardiovascular Business (August 28, 2026); Reuters (August 28, 2026). FDA Enforcement Action — Misleading Compounded GLP-1 Marketing (March 3, 2026): On March 3, 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading marketing claims about compounded GLP-1 receptor agonist products, including claims implying equivalence to FDA-approved brand-name medications (Ozempic, Wegovy, Mounjaro, Zepbound) and branding that obscured the identity of the actual compounder. This is a distinct enforcement action — separate from the 503B exclusion proposal (April 30, 2026) — and targets promotional violations rather than compounding authorization. Researchers and clinicians following this space should be aware that FDA is actively enforcing truthful labeling rules in the compounded GLP-1 market. Source: FDA press announcement (fda.gov, March 3, 2026); Reuters (March 3, 2026). Fifth Circuit Court of Appeals — GLP-1 Compounding Ruling (August 27, 2026): On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed two lower-court judgments upholding the FDA's removal of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) from the national drug shortage list. Because federal law (21 U.S.C. § 353a/353b) only permits compounding copies of an approved drug while it remains in shortage, this ruling removes the shortage-based legal basis for bulk compounding of these agents. 503A patient-specific compounding for individual patients with documented medical needs remains a separate, narrower pathway. 503B outsourcing facility bulk production of essentially-equivalent copies is no longer supported by a shortage justification. The ruling does not affect the separate FDA rulemaking (503B exclusion proposal, April 30, 2026) which is still under agency review. Sources: teleranked.com (August 27, 2026); peptidesbeat.com (August 27, 2026); courthousenews.com. FDA Import Alert 66-80 — GLP-1 API Detention (August 21, 2026): On August 21, 2026, the FDA published a major revision to Import Alert 66-80, authorising Detention Without Physical Examination (DWPE) of foreign-sourced GLP-1 receptor agonist bulk drug substances — including semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, and related peptide APIs — at U.S. ports of entry. The alert accompanies the FDA's "green list" program: manufacturers that have passed FDA inspection and cGMP review can apply to be exempted from automatic detention. Facilities that have not responded to FDA inspection requests or have been found non-compliant remain subject to DWPE. Practically, this means bulk GLP-1 API imported from foreign sources without green-list status can be detained and refused entry without individual inspection. This is a supply-chain enforcement tool targeting the import of raw GLP-1 peptide APIs used in compounding; it does not change whether compounding is otherwise permitted. The alert operates in parallel with the ongoing 503B exclusion rulemaking (comment period closed July 30, 2026, final rule pending) and the Fifth Circuit ruling (August 27, 2026) upholding removal of these agents from shortage status. Source: FDA Import Alert 66-80, accessdata.fda.gov (August 21, 2026); FDA press announcement (fda.gov); Frier Levitt (frierlevitt.com); PeptideKnow.com. FDA Warning Letter — Empower Pharmacy (September 18, 2026): On September 18, 2026, the FDA issued a warning letter (MARCS-CMS 738238) to Empower Clinic Services, LLC dba Empower Pharmacy (Houston, TX) — one of the largest 503A compounding pharmacies in the United States. The FDA cited three compounded semaglutide and tirzepatide presentations — including vitamin-blend formulations — as essentially copies of FDA-approved Ozempic, Wegovy, Mounjaro, and Zepbound, stripping them of the 503A exemptions from CGMP requirements, adequate directions for use, and premarket approval. The letter also cited insanitary conditions and violations relating to the scale of production, arguing the volume exceeded what qualifies as patient-specific 503A compounding. This is the third FDA warning letter Empower has received related to GLP-1 compounding. Empower has 15 business days to respond. The letter does not constitute a mandatory recall or facility closure, but escalates FDA's enforcement posture significantly against high-volume 503A compounding of GLP-1 agents. Source: FDA warning letter MARCS-CMS 738238, fda.gov (September 18, 2026); Endpoints News (September 23, 2026); Partnership for Safe Medicines (September 23, 2026). ANVISA Brazil Enforcement (October 6, 2026): Brazil's National Health Surveillance Agency (Anvisa) published Resolution RE nº 3.947/2026 in the Diário Oficial da União, prohibiting the sale, manufacture, distribution, advertising, transport, and use of multiple unregistered injectable peptide products marketed online without Anvisa registration, notification, or cadastro. Named products included BPC157 & TB500 combinations (Alluvi Healthcare), NAD+ 1000 mg (Synedica Labs), Tirzegen 60 mg tirzepatide (Oxygen Pharm), Retagen 40 mg retatrutide and other retatrutide vials (Oxygen Pharm / Alluvi Healthcare), and Glow GHK-CU 70 mg (Alluvi Healthcare), sold via peptideospro.com and peptideosdobrasil.com.br. The order applies to any natural or legal person and to media outlets; products are subject to seizure. This is a Brazil-specific enforcement action against unregistered commercial products and does not change FDA 503A/503B compounding status or U.S. approval pathways. Sources: Anvisa news release (gov.br/anvisa, October 6, 2026); Resolução RE nº 3.947 de 2 de outubro de 2026 (in.gov.br). MHRA UK Enforcement — Counterfeit Retatrutide/Tirzepatide Pens (October 14–15, 2026): On 14 October 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) Criminal Enforcement Unit and West Midlands Police raided an industrial unit in Birmingham and seized over 12,000 counterfeit weight-loss pens labelled as retatrutide and tirzepatide, plus packaging material for around 30,000 further products, with an estimated street value of approximately £2 million. MHRA stated that retatrutide has not been authorised for use in the UK and that products sold as retatrutide outside legitimate clinical trials are supplied illegally and may pose serious public-health risks; consumers were urged to obtain weight-loss medicines only from registered pharmacies against a valid prescription. The raid continues a series of MHRA operations removing tens of thousands of unauthorised GLP-1 weight-loss medicine doses from circulation. This is a UK criminal-enforcement action against counterfeit/unauthorised injectables and does not change FDA 503A/503B compounding status or U.S. approval pathways. Source: GOV.UK / MHRA press release (gov.uk, 15 October 2026).